Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to limit heart damage after attack

NCT ID NCT07362446

First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tests a medicine called Xolatryp in adults who have had a severe type of heart attack (STEMI) and are getting a procedure to open the blocked artery. Participants receive either Xolatryp or a placebo as a one-time IV infusion over 6 hours. The study checks if the drug is safe and helps the heart recover better, using blood tests, ECGs, and heart imaging over 30 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Liverpool Hospital

    NOT_YET_RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • Nepean Hospital

    RECRUITING

    Kingswood, New South Wales, 2747, Australia

  • Northern Health

    NOT_YET_RECRUITING

    Epping, Victoria, 3076, Australia

  • Royal Adelaide Hospital

    NOT_YET_RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Sir Charles Gairdner Hospital

    NOT_YET_RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Sunshine Hospital

    NOT_YET_RECRUITING

    Saint Albans, Victoria, 3021, Australia

Conditions

Explore the condition pages connected to this study.